Renal & Urinary

Hematuria: workup algorithm in adults

Clinical Overview and When to Suspect Hematuria

— Gross hematuria = visible blood in urine; any single episode in an adult mandates workup.

— Trace dipstick + 0 RBC/HPF on micro is not hematuria (think myoglobin, hemoglobin, beets, rifampin, phenazopyridine).

— Age >40, smoking history (current or ≥30 pack-years), occupational exposure (aromatic amines, benzene — painters, hairdressers, rubber/dye workers), pelvic radiation, cyclophosphamide use.

— Gross hematuria, irritative voiding symptoms without infection, chronic indwelling catheter, analgesic abuse.

— Family history of urothelial cancer, Lynch syndrome, or hereditary nephritis (Alport).

— Glomerular: dysmorphic RBCs, RBC casts, proteinuria >500 mg/day, HTN, elevated Cr, edema.

— Urologic: clots, terminal hematuria, flank pain, dysuria, smoking, age >40.

Definition (AUA 2020): Microscopic hematuria = ≥3 RBCs/HPF on a single, properly collected midstream urine microscopy. Dipstick alone is not diagnostic — must confirm with microscopy.

Epidemiology: Microhematuria prevalence 2–20% in adults; up to 5% harbor urologic malignancy, rising sharply with age, smoking, and gross hematuria.

When to suspect a serious cause:

Glomerular vs urologic clues at the front door:

Step 3 management: Before launching a costly workup, always rule out benign mimics first — recent UTI (re-check urine 6 weeks after treatment), menstruation, vigorous exercise, recent instrumentation, trauma, or anticoagulant excess. Anticoagulation does not exempt the patient from evaluation — hematuria on warfarin/DOAC still warrants the standard workup because underlying pathology is present in up to 25%.

Board pearl: A single episode of gross hematuria in any adult is a red flag for malignancy until proven otherwise — full urologic + upper-tract evaluation regardless of age.

Presentation Patterns and Key History

— Initial hematuria (start of stream) → urethral source (urethritis, stricture, urethral cancer).

— Terminal hematuria (end of stream) → bladder neck or prostatic source (BPH, prostatitis, bladder trigone).

— Total hematuria (throughout) → bladder, ureter, or kidney.

— Painless gross hematuria, age >50, smoker → urothelial (bladder) carcinoma until disproven.

— Colicky flank pain radiating to groin → nephrolithiasis or clot colic.

— Dysuria, frequency, urgency + fever → UTI/pyelonephritis; recheck urine after treatment.

— Hematuria 1–2 days after URI ("synpharyngitic") → IgA nephropathy.

— Hematuria 1–3 weeks post-pharyngitis or impetigo → post-streptococcal GN.

— Hemoptysis + hematuria → anti-GBM (Goodpasture) or ANCA vasculitis.

— Sensorineural hearing loss + family history → Alport syndrome (X-linked, COL4A5).

— Sickle cell trait/disease → painless hematuria from renal papillary necrosis or rare renal medullary carcinoma.

— Tobacco (single biggest modifiable risk for urothelial cancer), occupational dyes/solvents, schistosomiasis travel (squamous cell bladder cancer), pelvic radiation, cyclophosphamide (hemorrhagic cystitis → bladder cancer), chronic phenacetin/NSAIDs (papillary necrosis), anticoagulants.

— Recent strenuous exercise ("marathoner's hematuria") — resolves in 48–72 h; re-test before workup.

Timing within the stream localizes the source:

Associated symptoms — pattern recognition:

Exposure and medication history:

Family history: Polycystic kidney disease, Alport, sickle cell, Lynch syndrome (upper tract urothelial carcinoma), hereditary RCC syndromes (VHL, BHD).

Key distinction: Brown/cola-colored urine with proteinuria and HTN = glomerular (nephritic). Bright red urine with clots = post-glomerular (urologic) — clots cannot form when blood passes through the glomerulus.

Board pearl: Always ask about recent menstruation in women before labeling microhematuria — repeat UA after cycle ends.

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Hypertension + edema → glomerular disease.

— Fever + flank pain + costovertebral tenderness → pyelonephritis or perinephric abscess.

— Tachycardia, orthostasis, or pallor with gross hematuria + clots → assess for hemodynamically significant blood loss; gross hematuria rarely causes shock unless tumor erosion or major trauma — look for alternative source.

— Palpable purpura on lower extremities → IgA vasculitis (HSP) or ANCA-associated vasculitis.

— Malar rash, oral ulcers, alopecia → lupus nephritis.

— Petechiae, ecchymoses → coagulopathy or thrombocytopenia.

— Saddle-nose deformity, nasal crusting → granulomatosis with polyangiitis.

— Sensorineural hearing loss, anterior lenticonus → Alport.

— Hemoptysis, pulmonary rales → pulmonary-renal syndrome (anti-GBM, ANCA, lupus).

— Sinusitis, otitis → GPA.

— Palpable flank mass → renal cell carcinoma, hydronephrosis, or polycystic kidneys (bilateral, knobby).

— CVA tenderness → pyelonephritis, stone, infarct.

— Distended bladder → outlet obstruction with clot retention — needs 3-way Foley + continuous bladder irrigation.

— DRE in men >40: prostate size, nodules, tenderness (prostatitis).

— Meatal lesions, urethral discharge, foreskin pathology.

— Pelvic exam in women to exclude vaginal/cervical bleeding masquerading as hematuria.

Vital signs first:

Skin and mucosa:

HEENT and pulmonary:

Abdomen and flank:

Genitourinary exam (do not skip):

CCS pearl: When a patient presents with gross hematuria + clots + inability to void, the immediate next order is large-bore (22–24 Fr) 3-way urethral catheter with manual clot evacuation, then continuous bladder irrigation with normal saline — before any imaging or labs. Document urine output and clot resolution before transferring care.

Board pearl: A left-sided varicocele that does not decompress when supine in an adult man → suspect left renal vein obstruction by RCC.

Diagnostic Workup — Initial Labs and Imaging

— Dipstick positive → microscopy of fresh, midstream, non-traumatic catch. ≥3 RBC/HPF confirms.

— Dipstick positive + no RBCs → myoglobinuria (rhabdo, CK elevated) or hemoglobinuria (hemolysis, low haptoglobin).

— Repeat UA to exclude transient causes (menses, exercise, recent UTI, instrumentation within 48 h).

— Dysmorphic RBCs, acanthocytes (>5%), RBC casts, proteinuria → glomerular → nephrology workup.

— Isomorphic RBCs, clots, no proteinuria → urologic → urology workup.

— CBC, BMP (creatinine, eGFR), urinalysis with micro, urine protein-to-creatinine ratio or spot albumin/creatinine, coagulation panel if anticoagulated.

— If glomerular pattern suspected: C3/C4, ANA, anti-dsDNA, ANCA, anti-GBM, ASO, hepatitis B/C, HIV, complement, SPEP/UPEP.

— If stone suspected: serum calcium, uric acid; 24-h urine later.

— Low risk (women <50/men <40, never-smoker or <10 pack-years, 3–10 RBC/HPF, no risk factors): shared decision-making — repeat UA in 6 months or cystoscopy + renal US.

— Intermediate risk (50–59, 10–30 pack-years, 11–25 RBC/HPF): cystoscopy + renal ultrasound.

— High risk (≥60, >30 pack-years, >25 RBC/HPF, gross hematuria, prior occupational/radiation/cyclophosphamide exposure): cystoscopy + CT urography (multiphase CT with delayed excretory imaging).

Step 1 — Confirm true hematuria:

Step 2 — Characterize the bleeding source on UA:

Initial labs (all patients):

AUA 2020 risk-stratified imaging for microhematuria:

Step 3 management: For any gross hematuria in an adult, default to high-risk pathway: CT urography + cystoscopy regardless of age. Do not under-image because the patient is "young" — smoking and chemical exposures shift risk dramatically.

Board pearl: Urine cytology is no longer routine in the initial AUA microhematuria workup — reserve for persistent irritative symptoms or risk factors after negative cystoscopy.

Diagnostic Workup — Advanced or Confirmatory Studies

— Indicated for all patients ≥40 with microhematuria and all adults with gross hematuria.

— Direct visualization of urethra, prostate, bladder mucosa, ureteral orifices; gold standard for bladder lesions.

— White-light cystoscopy ± blue-light cystoscopy with hexaminolevulinate improves CIS detection.

— CT urography (CTU) — preferred for high-risk patients; detects stones, masses, urothelial lesions of renal pelvis/ureter.

— MR urography — alternative when iodinated contrast contraindicated; less sensitive for stones.

— Renal ultrasound + non-contrast CT — used when CTU contraindicated; lower sensitivity for upper-tract urothelial carcinoma.

— Retrograde pyelography at cystoscopy if upper tract poorly visualized.

— Glomerular pattern (dysmorphic RBCs, RBC casts, proteinuria >500 mg/day) with rising Cr, suspected RPGN, or unexplained CKD.

— Defer biopsy in isolated microhematuria with normal Cr/protein → outpatient nephrology follow-up.

— 24-h urine for stone formers (calcium, oxalate, citrate, uric acid, sodium, volume).

— Urine cytology / FISH (UroVysion) — selective use for high-risk surveillance or post-treatment monitoring of urothelial cancer.

— Hemoglobin electrophoresis if sickle cell suspected (especially Black patients with painless hematuria).

— Audiometry + ophthalmology if Alport suspected; genetic testing for COL4A3/4/5.

Cystoscopy:

Upper tract imaging — choose by risk and renal function:

Renal biopsy — indicated when:

Specialized studies:

Key distinction: CTU vs CT stone protocol — CTU includes IV contrast with delayed (excretory) phase to opacify the collecting system and identify urothelial filling defects; a non-contrast "stone protocol" CT misses urothelial cancer entirely.

Board pearl: Persistent microscopic hematuria after a negative initial workup → repeat UA annually for 1–2 years; if persistent + new risk factors emerge (e.g., gross hematuria, irritative symptoms), repeat full evaluation. Don't dismiss recurrent findings.

Risk Stratification and First-Line Management Logic

— Low risk — all of: women <50 or men <40, never-smoker or ≤10 pack-years, 3–10 RBC/HPF on a single UA, no risk factors (no gross hematuria, no irritative symptoms, no occupational exposure).

Action: Shared decision — either repeat UA within 6 months or cystoscopy + renal US. If repeat UA negative, no further workup.

— Intermediate risk — any of: women 50–59 or men 40–59, 10–30 pack-years, 11–25 RBC/HPF, OR a low-risk patient with persistent microhematuria on repeat.

Action: Cystoscopy + renal ultrasound.

— High risk — any of: age ≥60, >30 pack-years, >25 RBC/HPF on any UA, gross hematuria, history of pelvic radiation, cyclophosphamide, occupational exposure to benzene/aromatic amines, chronic indwelling catheter, prior urothelial cancer.

Action: Cystoscopy + CT urography.

— Refer nephrology if proteinuria >500 mg/day, elevated Cr, HTN, RBC casts, or systemic features.

— Begin ACEi/ARB if proteinuria + HTN.

— Empiric treatment never replaces tissue diagnosis when RPGN suspected (Cr doubling over weeks → biopsy ASAP).

— Large-bore (22–24 Fr) 3-way catheter, manual clot evacuation, continuous bladder irrigation with NS.

— Type & screen, CBC, coags; transfuse for Hgb <7 (or <8 in cardiac disease).

— Hold anticoagulants if life-threatening bleed; reverse warfarin with 4-factor PCC + vitamin K; reverse dabigatran with idarucizumab, factor Xa inhibitors with andexanet alfa or PCC.

The AUA 2020 three-tier microhematuria framework:

Glomerular-pattern hematuria pathway:

Acute gross hematuria with clots — first-line management:

CCS pearl: Order urology consult immediately for gross hematuria with clot retention; while awaiting consult, place 3-way Foley, start CBI, send labs, hold anticoagulants. Document urine clearing trend q4h.

Board pearl: Hematuria in a patient on anticoagulation is never adequately explained by the anticoagulant alone — full workup still required.

Pharmacotherapy — First-Line Drug Regimen

— Uncomplicated cystitis: nitrofurantoin 100 mg BID × 5 days (avoid if CrCl <30) or TMP-SMX DS BID × 3 days (if local resistance <20%) or fosfomycin 3 g × 1.

— Pyelonephritis (outpatient): ciprofloxacin 500 mg BID × 7 days or TMP-SMX DS BID × 14 days; ceftriaxone 1 g IV × 1 first if hospitalizing.

— Repeat UA 6 weeks post-treatment to confirm resolution; persistent hematuria mandates workup.

— Pain: ketorolac 15–30 mg IV (preferred unless AKI) or morphine.

— Medical expulsive therapy for ureteral stones 5–10 mm: tamsulosin 0.4 mg daily × up to 4 weeks.

— Antiemetics; IV fluids; strain urine.

— 5-alpha reductase inhibitor (finasteride 5 mg or dutasteride 0.5 mg daily) reduces prostatic vascularity and recurrent hematuria over 3–6 months; first-line for BPH bleeding.

— Alpha-blockers (tamsulosin) for LUTS but do not reduce bleeding.

— IgA nephropathy: ACEi/ARB + BP control to <125/75; add SGLT2 inhibitor; corticosteroids only if proteinuria persists >1 g/day after 90 days of optimized RAAS blockade.

— Lupus nephritis class III/IV: MMF or cyclophosphamide + steroids.

— ANCA vasculitis: rituximab or cyclophosphamide + high-dose steroids.

— Anti-GBM: plasmapheresis + cyclophosphamide + steroids.

— Prevent with mesna + aggressive hydration; treat with CBI, intravesical alum, formalin, or hyperbaric O₂ if severe.

Hematuria itself is a sign, not a disease — pharmacotherapy targets the underlying cause. Common Step 3 scenarios:

Urinary tract infection (most common cause of transient hematuria):

Nephrolithiasis with hematuria:

BPH-related hematuria:

Glomerular disease — disease-specific:

Hemorrhagic cystitis (cyclophosphamide/ifosfamide):

Board pearl: Phenazopyridine relieves dysuria but turns urine orange-red and stains contact lenses — counsel patients and avoid in G6PD deficiency.

Procedures and Invasive Management

— Office-based, flexible scope, local anesthesia.

— Biopsy of any suspicious lesion; CIS appears as red velvety patches.

— TURBT (transurethral resection of bladder tumor) — both diagnostic and therapeutic for non-muscle-invasive bladder cancer (NMIBC).

— NMIBC (Ta, T1, CIS) → TURBT + intravesical therapy:

– Low risk: single post-op intravesical mitomycin or gemcitabine.

– Intermediate/high risk: 6-week induction intravesical BCG + maintenance × 1–3 years.

— Muscle-invasive (≥T2) → neoadjuvant cisplatin-based chemo + radical cystectomy with pelvic LN dissection (or trimodal bladder-preservation: TURBT + chemoradiation in selected patients).

— Ureteroscopy with biopsy; radical nephroureterectomy with bladder cuff for high-grade or invasive tumors; kidney-sparing for low-grade, low-volume disease.

— Partial nephrectomy for T1 tumors (<7 cm) when feasible — preserves renal function.

— Radical nephrectomy for larger or central tumors; cytoreductive nephrectomy + systemic therapy (TKI, immunotherapy) for metastatic disease.

— Stones <10 mm: trial medical expulsive therapy.

— 10–20 mm or refractory: shockwave lithotripsy (SWL) or ureteroscopy with laser lithotripsy.

— >20 mm or staghorn: percutaneous nephrolithotomy (PCNL).

— Obstructed + infected stone (urosepsis): emergent decompression with ureteral stent or percutaneous nephrostomy — antibiotics alone insufficient.

Cystoscopy — primary diagnostic procedure for bladder, urethral, prostatic lesions:

Bladder cancer staging-driven treatment:

Upper tract urothelial carcinoma:

Renal cell carcinoma:

Nephrolithiasis procedures:

Refractory hemorrhagic cystitis: intravesical alum → formalin → hyperbaric oxygen → selective vesical artery embolization → urinary diversion as last resort.

CCS pearl: Obstructing ureteral stone + fever + leukocytosis = urologic emergency. Order urgent IV antibiotics (piperacillin-tazobactam or ceftriaxone), fluid resuscitation, and call urology for same-day stent or nephrostomy — do not wait for stone passage.

Special Populations — Elderly and Renal/Hepatic Impairment

— Pretest probability of malignancy is high — always default to high-risk imaging pathway (CTU + cystoscopy) for any hematuria, even microscopic.

— Comorbid BPH is common but does not exclude concurrent malignancy; finasteride trial only after structural disease excluded.

— Higher rates of anticoagulation use — full workup still mandatory.

— Frailty assessment before invasive imaging or cystectomy — consider G8 or Clinical Frailty Scale; shared decision-making about workup intensity if life expectancy <5 years and patient declines treatment regardless of findings.

— Avoid iodinated contrast when possible — use renal ultrasound + non-contrast MR urography or retrograde pyelography.

— If CT urography essential, hydrate with isotonic saline; no role for N-acetylcysteine or bicarbonate (per 2020 evidence).

— Gadolinium: avoid group 1 agents (gadodiamide) in eGFR <30 due to nephrogenic systemic fibrosis risk; group 2 macrocyclic agents (gadobutrol, gadoteridol) are lower risk but still used cautiously.

— Adjust antibiotic doses: nitrofurantoin contraindicated if CrCl <30; ciprofloxacin and TMP-SMX require renal dosing.

— Coagulopathy from cirrhosis may unmask hematuria from minor lesions — correct INR if actively bleeding (FFP, vitamin K), but workup still indicated.

— Avoid nephrotoxic NSAIDs for stone pain in cirrhosis with ascites/HRS risk → use acetaminophen + low-dose opioid.

— Acquired cystic kidney disease increases RCC risk 30–100×; screen with annual renal US after 3+ years of dialysis.

— Hematuria in a dialysis patient with native kidneys → CTU or MR urography of native kidneys plus cystoscopy.

Elderly (≥65):

Chronic kidney disease (eGFR <30):

Hepatic impairment:

Dialysis patients:

Step 3 management: In an elderly patient on anticoagulation with microhematuria, do not stop anticoagulation pending workup unless bleeding is hemodynamically significant — proceed with imaging on therapy. Coordinate timing with urology if cystoscopy biopsy planned (typically hold DOAC 48 h).

Board pearl: Painless gross hematuria in an elderly smoker = bladder cancer until cystoscopy proves otherwise.

Special Populations — Pregnancy and Pediatric/Other Subgroups

— Most common cause: UTI / asymptomatic bacteriuria — treat all bacteriuria to prevent pyelonephritis and preterm labor (nitrofurantoin avoid in 1st trimester and at term; cephalexin or fosfomycin preferred; avoid TMP-SMX in 1st and 3rd trimesters).

— Nephrolithiasis: renal ultrasound first; MR urography (no gadolinium) if equivocal; low-dose non-contrast CT only if essential.

— Cystoscopy is safe in pregnancy — proceed if gross hematuria or high suspicion of malignancy.

— Mild proteinuria + hematuria after 20 weeks + HTN → preeclampsia workup (CBC, LFTs, uric acid, urine protein/Cr).

— IgA nephropathy — most common glomerular cause worldwide; "synpharyngitic" gross hematuria 1–2 days after URI.

— Thin basement membrane disease ("benign familial hematuria") — persistent isolated microhematuria, normal renal function, autosomal dominant, no treatment.

— Alport syndrome — hematuria + sensorineural hearing loss + lenticonus; X-linked dominant; progresses to ESRD in males.

— Strenuous exercise hematuria — resolves in 48–72 h.

— Test for sickle cell trait/disease — recurrent painless hematuria from renal papillary necrosis.

— Rule out renal medullary carcinoma (rare but aggressive; almost exclusively sickle cell trait, young patients) — CT/MRI of kidneys.

— Schistosoma haematobium (Sub-Saharan Africa, Middle East) → terminal hematuria, eggs in urine, long-term risk of squamous cell bladder cancer. Treat with praziquantel.

Pregnancy:

Young adults (<40):

Black patients with painless hematuria:

Travelers / immigrants:

Post-renal transplant: Hematuria + graft dysfunction → BK virus nephropathy, recurrent glomerulonephritis, ureteral stenosis, or PTLD; biopsy often required.

Board pearl: A child with hematuria + edema + HTN 1–3 weeks after pharyngitis = post-streptococcal GN — supportive care, low C3 normalizes within 8 weeks; if not, reconsider MPGN or lupus.

Key distinction: Thin basement membrane (benign) vs early Alport — family history of ESRD/hearing loss tips toward Alport; genetic testing clarifies.

Complications and Adverse Outcomes

— Bladder cancer: progression from NMIBC to muscle-invasive (~15% over 5 years); metastases to lymph nodes, lung, bone, liver; ureteral obstruction with hydronephrosis.

— Upper tract urothelial carcinoma: ipsilateral kidney loss after nephroureterectomy; metachronous bladder tumors in 30–50%.

— RCC: paraneoplastic syndromes (hypercalcemia from PTHrP, polycythemia from EPO, Stauffer syndrome — reversible hepatic dysfunction without metastases).

— Glomerulonephritis: progression to CKD/ESRD, especially RPGN if untreated (>50% ESRD within months).

— Nephrolithiasis: obstructive uropathy, urosepsis, recurrent stones (50% within 5 years without prevention).

— Clot retention with bladder distension → acute urinary retention, AKI from bilateral hydronephrosis, bladder rupture (rare).

— Anemia requiring transfusion.

— Hyponatremia from absorbed CBI fluid (TUR syndrome) if hypotonic irrigation used — always use isotonic NS.

— Contrast-associated AKI — risk overstated in modern practice but real in eGFR <30; hydration mitigates.

— Cystoscopy complications: UTI (5–10%), urethral trauma, transient hematuria; rare bladder perforation with biopsy.

— Renal biopsy: bleeding requiring transfusion (1–2%), AV fistula, perinephric hematoma; hold antiplatelets/anticoagulants pre-procedure.

— Intravesical BCG: cystitis, hematuria, BCG sepsis (rare, fatal if untreated — isoniazid + rifampin + ethambutol), granulomatous prostatitis.

— Cisplatin chemo: nephrotoxicity, ototoxicity, neuropathy.

— Cyclophosphamide: hemorrhagic cystitis (paradoxical — the very drug used for vasculitis-related hematuria), infertility, secondary bladder cancer 10–15 years later.

From the underlying disease:

From acute gross hematuria:

From workup itself:

From treatment:

Step 3 management: Counsel all post-cyclophosphamide patients on lifelong annual UA screening for delayed bladder cancer — a classic Step 3 secondary prevention prompt.

Board pearl: TUR syndrome (hyponatremic encephalopathy from glycine/sorbitol absorption) is now rare since adoption of bipolar TURBT with isotonic saline irrigation — but still tested.

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Hemodynamic instability from hematuria (rare): tachycardia, hypotension, Hgb drop >2 g/dL.

— Clot retention with inability to void → ED for 3-way catheter, manual evacuation, CBI; admit if irrigation cannot be discontinued.

— Obstructing stone + fever / sepsis → emergent IV antibiotics + urgent decompression (stent or nephrostomy within 6–12 h).

— Anuria or bilateral hydronephrosis with AKI.

— Suspected renal trauma with hemodynamic instability or expanding hematoma.

— Gross hematuria with clots.

— High-risk microhematuria findings (mass on imaging, suspicious cytology).

— Refractory hemorrhagic cystitis.

— Suspected upper tract obstruction.

— Rapidly rising creatinine + active urinary sediment (RBC casts, dysmorphic RBCs) → suspect RPGN → urgent biopsy and empiric pulse steroids may be life- and kidney-saving.

— Suspected pulmonary-renal syndrome (hemoptysis + hematuria + AKI) → ICU-level care, plasmapheresis availability.

— Nephrotic-range proteinuria with hematuria.

— Pulmonary hemorrhage from anti-GBM or ANCA vasculitis.

— Massive hematuria with hemodynamic compromise requiring transfusion + angiographic embolization.

— Urosepsis with shock.

— Severe hyponatremia from TUR syndrome (Na <120 with seizures).

— Persistent gross hematuria not clearing with CBI.

— Need for transfusion + ongoing bleeding.

— Pyelonephritis with comorbidities, pregnancy, or failed outpatient therapy.

Emergency department / immediate admission criteria:

Urology consult — same day:

Nephrology consult — same day to 48 h:

ICU admission triggers:

Hospital admission (non-ICU):

CCS pearl: Suspected RPGN — order renal biopsy within 24–48 h and start empiric pulse methylprednisolone 500–1000 mg IV daily × 3 days while awaiting tissue if anti-GBM or ANCA strongly suspected; delay = irreversible nephron loss.

Board pearl: Obstruction + infection above a stone = "pus under pressure" — antibiotics alone are insufficient; decompression is the definitive intervention.

Key Differentials — Same-Category (Urologic/Renal) Causes

— Kidney/upper tract:

– Renal cell carcinoma — classic triad (hematuria + flank pain + palpable mass) <10%; most found incidentally on imaging.

– Upper tract urothelial carcinoma — flank pain + hematuria; Lynch syndrome association.

– Renal stones — colicky pain, hematuria in 85%.

– Pyelonephritis — fever, CVA tenderness, pyuria.

– Renal infarction — AFib, sudden flank pain, elevated LDH.

– Papillary necrosis — sickle cell, diabetes, analgesic abuse, obstruction; "ring sign" on CTU.

– Polycystic kidney disease — bilateral flank masses, family history, intracranial aneurysms.

– Renal vein thrombosis — nephrotic syndrome (especially membranous).

— Ureter:

– Stones, urothelial carcinoma, strictures, retroperitoneal fibrosis.

— Bladder:

– Urothelial carcinoma — painless gross hematuria, smoker, age >50; most common urologic cancer cause of hematuria in adults.

– Hemorrhagic cystitis — cyclophosphamide, ifosfamide, radiation, BK virus (post-transplant), adenovirus (pediatric).

– Bacterial cystitis, eosinophilic cystitis, schistosomiasis.

– Bladder stones, foreign body, indwelling catheter trauma.

— Prostate:

– BPH — most common cause of gross hematuria in older men after malignancy excluded.

– Prostate cancer, prostatitis.

— Urethra:

– Urethritis (gonorrhea, chlamydia), urethral stricture, urethral cancer, trauma (catheterization), caruncle (postmenopausal women).

Urologic (post-glomerular) — by anatomic location:

Key distinction: RCC vs angiomyolipoma vs oncocytoma on CT — AML has macroscopic fat (negative HU on CT) and is benign; oncocytoma has central scar but cannot be reliably distinguished from RCC → resection or biopsy.

Board pearl: Painless gross hematuria + smoking + age >50 = bladder cancer until cystoscopy proves otherwise. Never attribute to BPH without ruling out malignancy first.

Key Differentials — Other-Category (Glomerular & Systemic) Causes

— IgA nephropathy (Berger disease) — most common primary GN worldwide; synpharyngitic gross hematuria 1–2 days after URI; normal C3/C4; treat with ACEi/ARB ± steroids if persistent proteinuria.

— Post-infectious GN — 1–3 weeks after strep pharyngitis/impetigo; low C3, normal C4, positive ASO/anti-DNase B; supportive care.

— Lupus nephritis — class III/IV/V; low C3 and C4, anti-dsDNA, ANA; treat per ISN class.

— MPGN — low C3 and C4; cryoglobulinemia (HCV-associated) or complement-mediated.

— Anti-GBM (Goodpasture) — hemoptysis + hematuria + AKI; linear IgG on biopsy; plasmapheresis + cyclophosphamide + steroids.

— ANCA-associated vasculitis (GPA, MPA, EGPA) — pauci-immune crescentic GN; rituximab or cyclophosphamide.

— Alport syndrome — hereditary; hematuria + hearing loss + lenticonus.

— Thin basement membrane disease — benign isolated familial hematuria.

— Coagulopathy, anticoagulant excess, thrombocytopenia.

— Sickle cell disease/trait — papillary necrosis, renal medullary carcinoma.

— Endocarditis — embolic glomerulonephritis ("flea-bitten kidney").

— Schistosomiasis, TB of GU tract (sterile pyuria + hematuria), HIV-associated nephropathy.

— Myoglobinuria (rhabdo), hemoglobinuria (hemolysis).

— Beets, blackberries, rhubarb (anthocyanins).

— Rifampin, phenazopyridine, phenytoin, methyldopa, doxorubicin, levodopa, nitrofurantoin — pigmenturia.

— Porphyria — urine darkens on standing.

Glomerular diseases (think "RBC casts, dysmorphic RBCs, proteinuria"):

Systemic / extrarenal mimics and contributors:

Pseudohematuria (no RBCs on micro):

Key distinction: Low C3 with hematuria narrows to: post-infectious GN, lupus, MPGN, cryoglobulinemic vasculitis, atheroembolic disease, endocarditis-associated GN, shunt nephritis.

Board pearl: Hematuria + hemoptysis = pulmonary-renal syndrome — order anti-GBM, ANCA, ANA, anti-dsDNA, complement stat; biopsy and treat empirically while awaiting results.

Secondary Prevention, Discharge Medications, Long-Term Plan

— Repeat UA annually for 2 years. If persistent or new gross hematuria, repeat full evaluation.

— Counsel on smoking cessation — single most important modifiable risk factor for urothelial cancer; offer varenicline or nicotine replacement + behavioral support.

— Limit occupational/environmental exposure to aromatic amines; advocate PPE.

— Cystoscopy + cytology every 3 months for 2 years, then every 6 months × 2 years, then annually.

— Upper tract imaging (CTU) every 1–2 years for high-grade disease.

— Intravesical BCG maintenance × 1–3 years for high-risk NMIBC.

— Stage I after partial/radical nephrectomy: history, exam, labs every 6 months × 2 years, then annually; CT abdomen/chest at 12 months and as indicated.

— Higher stages: more intensive imaging schedule.

— Fluid intake ≥2.5 L/day (universal).

— 24-h urine 6 weeks after stone passage; tailor by abnormality:

– Hypercalciuria: thiazide (HCTZ 25 mg) + low-sodium diet, normal-calcium diet (do NOT restrict calcium — increases oxalate absorption).

– Hypocitraturia: potassium citrate.

– Hyperuricosuria/uric acid stones: alkalinize urine to pH 6.5–7 with potassium citrate; allopurinol if serum uric acid high.

– Cystinuria: hydration, alkalinization, tiopronin/d-penicillamine.

— ACEi/ARB titrated to BP <130/80 (KDIGO 2021) and proteinuria <500 mg/day.

— SGLT2 inhibitor (dapagliflozin, empagliflozin) — proven benefit in proteinuric CKD (DAPA-CKD, EMPA-KIDNEY).

— Statin per ASCVD risk; pneumococcal and influenza vaccines if immunosuppressed.

Post-workup follow-up for negative microhematuria evaluation:

Post-bladder cancer surveillance (NMIBC):

Post-RCC surveillance (NCCN-stratified by stage):

Stone disease secondary prevention:

Glomerular disease long-term:

Step 3 management: Schedule smoking cessation counseling at every visit for any patient with urothelial pathology — bill it as a separate covered preventive service (CMS code 99406/99407).

Board pearl: Calcium restriction for calcium oxalate stones is a wrong answer — normal dietary calcium binds oxalate in gut.

Follow-Up, Monitoring Parameters, and Counseling

— Negative low-risk workup: annual UA × 2 years.

— Negative intermediate/high-risk workup: annual UA + re-evaluate if gross hematuria, irritative symptoms, or new risk factor; consider repeat cystoscopy at 3–5 years for persistent microhematuria with high risk.

— Glomerular hematuria with normal renal function: UA, BMP, urine protein/Cr every 6–12 months; nephrology every 6–12 months.

— Active glomerulonephritis on immunosuppression: monthly visits initially; CBC, BMP, UA, drug levels (tacrolimus, MMF); monitor for infection.

— Serum creatinine and eGFR trend.

— Urine protein/Cr ratio or albumin/Cr ratio.

— Blood pressure (home log preferred; target <130/80 for CKD).

— Hemoglobin (chronic blood loss anemia).

— UA microscopy: RBC count, casts, proteinuria.

— Smoking cessation at every visit. Document readiness stage; provide pharmacotherapy + behavioral referral.

— Hydration — 2–2.5 L/day (especially stone-formers, sickle cell, cyclophosphamide users).

— Diet: DASH-style; reduce sodium, animal protein, and oxalate-rich foods (for oxalate stone formers).

— Avoid nephrotoxins: NSAIDs in CKD, IV contrast when avoidable, herbal supplements (aristolochic acid → upper tract urothelial cancer).

— Report any new gross hematuria, fever, flank pain, or decreased urine output immediately.

— Post-cystectomy: stoma care for ileal conduit, pelvic floor PT for orthotopic neobladder, sexual function counseling.

— Post-nephrectomy: nephrology referral if eGFR <60 or single kidney; lifelong BP and proteinuria monitoring.

Outpatient cadence after initial workup:

Parameters to track:

Patient counseling — universal:

Rehabilitation considerations:

Vaccinations: Annual influenza, COVID-19 boosters per CDC, pneumococcal (PCV15/PCV20 + PPSV23), shingles ≥50.

Step 3 management: For post-radical cystectomy patient on ileal conduit, expect non-anion gap metabolic acidosis (chloride absorption from intestinal segment) — monitor BMP every 3 months; treat with oral bicarbonate if symptomatic or HCO₃ <20.

Board pearl: Persistent microhematuria + new proteinuria = repeat evaluation, including nephrology referral.

Ethical, Legal, and Patient Safety Considerations

— Discuss risks (UTI, urethral trauma, contrast reaction, radiation), benefits (cancer detection), and alternatives (renal US instead of CTU in select patients). Document shared decision-making.

— Patients with limited English proficiency require certified medical interpreter — family members are inappropriate per Joint Commission and Title VI of the Civil Rights Act.

— Elderly patient with dementia and gross hematuria: assess decision-making capacity; if lacking, identify legal surrogate per state hierarchy. If patient previously expressed values declining invasive workup, honor advance directive.

— Suspected malignancy in a frail patient: shared decision-making — workup only if results would change management.

— Failure to follow up incidental microhematuria is a leading cause of missed bladder cancer diagnosis and malpractice claims. Ensure closed-loop communication: document patient notification, schedule follow-up appointment before discharge, and confirm receipt.

— Post-discharge medication reconciliation after gross hematuria: restart anticoagulation only after urology clearance; provide written instructions on when and how to resume.

— Handoffs from ED to outpatient: explicitly communicate need for urology referral; do not assume PCP will catch it.

— Suspected non-accidental trauma in a child with hematuria → mandatory report to child protective services.

— Suspected intimate partner violence in an adult with hematuria from blunt trauma → offer resources, document, follow state reporting laws (some states require reporting; most do not for competent adults).

— Occupational exposure (aromatic amine workers) → report to employer health/OSHA; workers' comp eligibility.

— Contrast allergy documentation — verify before CTU; premedicate with prednisone (50 mg PO 13, 7, 1 h pre) + diphenhydramine if prior moderate reaction.

— Radiation stewardship — track cumulative dose; use MR urography in young patients when feasible.

Informed consent for cystoscopy and CT urography:

Capacity and surrogate decision-making:

Transition-of-care risks (high-yield Step 3):

Mandatory reporting and legal duties:

Patient safety:

CCS pearl: Always document a scheduled follow-up appointment date and a named clinician before signing off on a hematuria patient — the most common malpractice scenario is the lost-to-follow-up microhematuria that becomes metastatic bladder cancer 3 years later.

High-Yield Associations and Rapid-Fire Clinical Facts

Painless gross hematuria + smoker + age >50 → bladder urothelial carcinoma.

Hematuria + flank pain + palpable mass → RCC (classic triad, present in <10%).

Hematuria + left varicocele not decompressing supine → left renal vein obstruction by RCC.

Hematuria 1–2 days after URI → IgA nephropathy.

Hematuria 1–3 weeks after pharyngitis → post-strep GN (low C3, normal C4).

Hematuria + hemoptysis + AKI → anti-GBM or ANCA vasculitis.

Hematuria + hearing loss + family history → Alport syndrome.

Hematuria + bilateral flank masses + family history → ADPKD (screen for berry aneurysms).

Hematuria + sickle cell trait + Black patient + young → renal medullary carcinoma (aggressive).

Terminal hematuria + travel to Egypt or Sub-Saharan Africa → schistosomiasis → squamous cell bladder cancer.

Hematuria + cyclophosphamide use → hemorrhagic cystitis; later bladder cancer risk × 10–15 yrs.

Hematuria + aristolochic acid (Chinese herbs) → upper tract urothelial carcinoma + Balkan nephropathy.

Hematuria + recent marathon → exercise-induced; resolves in 48–72 h, repeat UA.

Hematuria + AFib + sudden flank pain → renal artery embolism (LDH elevated).

Hematuria + nephrotic syndrome (especially membranous) → renal vein thrombosis.

Hematuria + palpable purpura + abdominal pain → IgA vasculitis (HSP).

Hematuria + low C3, normal C4 → post-strep GN.

Hematuria + low C3 and low C4 → lupus nephritis, MPGN, cryoglobulinemia, endocarditis GN.

Painless terminal hematuria in older man → BPH (after malignancy excluded).

Hematuria + chronic indwelling catheter >10 years → squamous cell bladder carcinoma.

Dipstick positive, no RBC → myoglobin (rhabdo, CK ↑) or hemoglobin (hemolysis, haptoglobin ↓).

Beets, rifampin, phenazopyridine → red urine, no hematuria.

Board pearl: "Painless gross hematuria" in an adult = cystoscopy + CT urography. This is the single most testable Step 3 hematuria phrase.

Key distinction: Glomerular hematuria has dysmorphic RBCs + RBC casts + proteinuria + no clots; urologic hematuria has isomorphic RBCs + clots + minimal proteinuria.

Board Question Stem Patterns

"A 62-year-old man with a 40 pack-year smoking history presents with one episode of bright red urine and clots. No pain, no dysuria. UA: >25 RBC/HPF, no protein. Cr normal."

→ Best next step: cystoscopy + CT urography (high-risk pathway). Wrong answers: renal US alone, urine cytology, repeat UA, finasteride trial.

"A 24-year-old man develops cola-colored urine 36 hours after URI symptoms. UA: 50 RBC/HPF, dysmorphic, RBC casts, 1+ protein. Cr 1.0. C3 and C4 normal."

→ Diagnosis: IgA nephropathy. Manage with ACEi if proteinuria; biopsy if progressive.

"9-year-old with periorbital edema, dark urine, BP 150/95 two weeks after pharyngitis. C3 low, C4 normal, ASO elevated."

→ Post-streptococcal GN — supportive care, salt/fluid restriction, antihypertensives.

"Cr rising from 1.0 to 3.5 over 3 weeks, RBC casts on UA, hemoptysis."

→ Order anti-GBM, ANCA, ANA; urgent renal biopsy; empiric pulse methylprednisolone.

"A 35-year-old woman never-smoker, 5 RBC/HPF, no symptoms, no protein."

→ Shared decision: repeat UA in 6 months or cystoscopy + renal US. Wrong: immediate CTU.

"Flank pain, fever 39°C, WBC 18, CT shows 8 mm stone with hydronephrosis."

→ IV antibiotics + urgent decompression (stent or nephrostomy). Antibiotics alone is wrong.

"Patient on warfarin, INR 2.5 therapeutic, 2 episodes gross hematuria."

→ Full workup still indicated — do not attribute to anticoagulation.

"Dark urine, dipstick blood positive, no RBCs on micro, CK 18,000."

→ Rhabdomyolysis with myoglobinuria. Aggressive IV fluids.

"Patient treated for GPA 12 years ago with cyclophosphamide, now gross hematuria."

→ Bladder cancer screening with cystoscopy + CTU.

Stem 1 — The smoker with painless hematuria:

Stem 2 — The young patient with synpharyngitic hematuria:

Stem 3 — Post-strep GN:

Stem 4 — RPGN:

Stem 5 — Microhematuria, low risk:

Stem 6 — Obstructing stone with infection:

Stem 7 — Anticoagulant + hematuria:

Stem 8 — Pseudohematuria:

Stem 9 — Post-cyclophosphamide surveillance:

Board pearl: When the stem says "painless gross hematuria," the answer is almost always cystoscopy + CT urography regardless of other distractors.

One-Line Recap

Hematuria in any adult — gross or persistent microscopic (≥3 RBC/HPF on microscopy) — demands risk-stratified evaluation, with cystoscopy + CT urography for high-risk patients (age ≥60, gross hematuria, >30 pack-years, occupational exposures, prior radiation/cyclophosphamide) and a parallel glomerular workup (dysmorphic RBCs, RBC casts, proteinuria → nephrology, biopsy if RPGN suspected), because failure to evaluate is the leading malpractice scenario for missed urothelial malignancy.

Confirm before pursuing: Dipstick positive → microscopy required; rule out menses, recent exercise, UTI (repeat UA 6 weeks after treatment), and instrumentation.

Risk-tier the workup (AUA 2020): Low risk → shared decision (repeat UA vs cystoscopy + US); intermediate → cystoscopy + US; high risk or any gross hematuria → cystoscopy + CT urography. Anticoagulation does not excuse workup.

Distinguish glomerular vs urologic at the bedside: Dysmorphic RBCs, RBC casts, and proteinuria → nephrology pathway with ACEi/ARB and possible biopsy; isomorphic RBCs with clots → urology pathway. Hematuria + hemoptysis = pulmonary-renal syndrome until proven otherwise.

Close the loop: Document patient notification, schedule follow-up before discharge, counsel on smoking cessation at every visit, and continue annual UA surveillance for 2 years after a negative high-risk workup — and lifelong UA in cyclophosphamide-exposed patients.

Board pearl: "Painless gross hematuria in an adult smoker" → cystoscopy + CT urography is the right answer, every time.